William Blair analyst Myles Minter downgraded Karuna Therapeutics (KRTX) to Market Perform from Outperform after the company agreed to be acquired by Bristol Myers (BMY) for $330 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRTX:
- M & A News: Bristol-Myers (NYSE:BMY) to Acquire Karuna for $14B
- Karuna Therapeutics’ KarXT results in schizophrenia published in The Lancet
- Karuna Therapeutics initiated with bullish view at Citi, here’s why
- Karuna Therapeutics initiated with bullish view at Deutsche Bank, here’s why
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
